Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders

Pediatric Blood & Cancer
Elise OcchipintiRandall Craver

Abstract

The category, cytology, cytogenetics (CCC) system for myelodysplastic syndrome (MDS) and the pediatric WHO system for MDS/myeloproliferative disorder (MPD) have recently been proposed to characterize these diseases in pediatrics. We compare the CCC and pediatric WHO systems against each other and against the French, American, British (FAB) and adult WHO classifications in order to determine which more accurately classifies these diseases and predicts outcome. An 18-year retrospective review identified patients less than 18 years of age meeting CCC and/or pediatric WHO criteria for the diagnosis of MDS or MPD. Resolution, stability, progression, and death in the subcategories of each system were compared. Twenty-eight patients were included in the study. Pediatric WHO: 17 patients met criteria, 10 died. Eight developed acute myelogenous leukemia (AML) (seven died), one juvenile myelomonocytic leukemia (JMML) (died), one chronic myelomonocytic leukemia (CMML) (currently in relapse), two died of complications, two responded to BMT, three have stable disease, one resolved. Eleven patients were not classifiable by the pediatric WHO system, one of which progressed to AML and died. CCC: 26 patients met criteria, 9 died. Nine developed...Continue Reading

References

Mar 1, 1996·British Journal of Haematology·E R VellosoH Van den Berghe
Aug 3, 2001·American Journal of Human Genetics·K KosakiN Matsuo
Oct 30, 2001·Leukemia·H SasakiUNKNOWN MDS Committee of the Japanese Society of Pediatric Hematology, Japan
Jul 27, 2002·Journal of Pediatric Hematology/oncology·Karen MandelMelvin H Freedman
Nov 15, 2002·Pediatric Clinics of North America·Blanche P Alter
Nov 26, 2002·Hematology·Alan D D'AndreaAkiko Shimamura

❮ Previous
Next ❯

Citations

Jan 17, 2007·Current Opinion in Pediatrics·Henrik Hasle
Mar 24, 2010·Pediatric Clinics of North America·Alan S WayneR Maarten Egeler
Jan 31, 2006·Journal of the European Academy of Dermatology and Venereology : JEADV·D GröneCh C Zouboulis

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.